Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Benznidazole
Treatment for Chagas disease
Typical Dosage: 5-7 mg/kg/day for adults, 5-10 mg/kg/day for children, divided into 2 doses
Effectiveness
75%
Safety Score
35%
Clinical Trials
22
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
5-7 mg/kg/day for adults, 5-10 mg/kg/day for children, divided into 2 doses
Time to Effect
Weeks to months for parasiticidal effect, years for clinical benefit
Treatment Duration
60 days
Evidence Quality
HIGHNumber Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$2,500
Side Effect Mgmt:$750
Total Annual:$4,750
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$11,570/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$7,917
Cost per Remission
$11,875
Comparison vs Nifurtimox
Cost Difference
$0/year
Same cost
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Benznidazole Outcomes
for Chagas disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+60%
Remission Rate
+40%
Common Side Effects
Dermatitis/Rash
+40%
Gastrointestinal disturbances (nausea, vomiting, abdominal pain)
+30%
Peripheral neuropathy
+15%
Myelosuppression
+7%
Hepatitis (elevated liver enzymes)
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
3 active trials recruiting for Benznidazole in Chagas disease
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
NCT04024163ACTIVE NOT RECRUITINGPHASE3
178 participants
INTERVENTIONAL
Buenos Aires, Argentina +8 more
Started: Sep 19, 2019
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
NCT04897516RECRUITINGPHASE3
300 participants
INTERVENTIONAL
Buenos Aires, Argentina +5 more
Started: Jul 28, 2021
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600RECRUITINGPHASE2
130 participants
INTERVENTIONAL
Sylmar, United States +18 more
Started: Apr 28, 2025
Completed Clinical Trials
13 completed trials for Benznidazole in Chagas disease
Population Pharmacokinetics of Benznidazole in Children With Chagas Disease
NCT00699387COMPLETEDNA
37 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Apr 1, 2007
Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.
NCT03191162COMPLETEDPHASE2
238 participants
INTERVENTIONAL
Buenos Aires, Argentina +6 more
Started: Apr 21, 2017
Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease
NCT01678599COMPLETEDPHASE4
220 participants
INTERVENTIONAL
Aiquile, Bolivia
Started: Apr 1, 2011
Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease
NCT01755403COMPLETEDPHASE4
52 participants
INTERVENTIONAL
Barcelona, Spain
Started: Dec 1, 2012
Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
NCT02386358COMPLETEDPHASE3
910 participants
INTERVENTIONAL
Ciudad Autónoma de Buenos Aires, Argentina
Started: Mar 1, 1999
New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease
NCT01755377COMPLETED
63 participants
OBSERVATIONAL
Barcelona, Spain
Started: Dec 1, 2012
Pharmacokinetic Drug-Drug Interaction Study
NCT03892213COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Oct 1, 2014
New Therapies and Biomarkers for Chagas Infection
NCT03981523COMPLETEDPHASE2
450 participants
INTERVENTIONAL
Cochabamba, Bolivia +2 more
Started: Dec 18, 2019
Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
NCT01162967COMPLETEDPHASE2
78 participants
INTERVENTIONAL
Santa Coloma, Spain +2 more
Started: Sep 1, 2010
Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
NCT03672487COMPLETEDPHASE3
87 participants
INTERVENTIONAL
San Diego, United States +2 more
Started: Jun 1, 2019
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
NCT00123916COMPLETEDPHASE3
2.85K participants
INTERVENTIONAL
Buenos Aires, Argentina +46 more
Started: Nov 1, 2004
Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease
NCT01549236COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Buenos Aires, Argentina +2 more
Started: May 1, 2011
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
NCT01377480COMPLETEDPHASE2
120 participants
INTERVENTIONAL
Started: Jul 6, 2011
Showing 20 of 22 total trials